Dissecting the roles and clinical potential of YY1 in the tumor microenvironment

MN Li, JX Wei, CN Xue, XT Zhou, SP Chen… - Frontiers in …, 2023 - frontiersin.org
Yin-Yang 1 (YY1) is a member of the GLI-Kruppel family of zinc finger proteins and plays a
vital dual biological role in cancer as an oncogene or a tumor suppressor during …

Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy

C Meo, F de Nigris - Cancers, 2024 - mdpi.com
Simple Summary Solid tumors create a hostile hypoxic microenvironment characterized by
abnormal vascularization and immune suppression. Target tumor vessels and the activation …

[HTML][HTML] Regulation of Krüppel-Like Factor 4 (KLF4) expression through the transcription factor Yin-Yang 1 (YY1) in non-Hodgkin B-cell lymphoma

M Morales-Martinez, A Valencia-Hipolito, GG Vega… - Oncotarget, 2019 - ncbi.nlm.nih.gov
Abstract Krüppel-Like Factor 4 (KLF4) is a member of the KLF transcription factor family, and
evidence suggests that KLF4 is either an oncogene or a tumor suppressor. The regulatory …

[HTML][HTML] Yin Yang 1 expression predicts a favourable survival in diffuse large B-cell lymphoma

T Xue, JX Lin, YQ He, JW Li, ZB Liu, YJ Jia, XY Zhou… - Heliyon, 2024 - cell.com
Abstract Aims Yin Yang 1 (YY1) is a multifunctional transcription factor that plays an
important role in tumour development and progression, while its clinical significance in …

Role of the transcription factor Yin Yang 1 and its selectively identified target Survivin in high-grade B-cells non-Hodgkin lymphomas: potential diagnostic and …

S Vivarelli, L Falzone, G Ligresti, S Candido… - International Journal of …, 2020 - mdpi.com
B-cell non-Hodgkin lymphomas (B-NHLs) are often characterized by the development of
resistance to chemotherapeutic drugs and/or relapse. During drug-induced apoptosis, Yin …

Cyclin D1+ large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge

D Gao, Z Liu - Biomarker Research, 2019 - Springer
Background A subset of diffuse large B-cell lymphoma may show aberrant cyclin D1
expression, which may be confused with blastoid mantle cell lymphoma. These cases …

Reversal of Resistance to Anti-CD20 Antibody Therapies: Targeting Intracellular Resistant Factors

I Navasardyan, B Bonavida - Critical Reviews™ in …, 2020 - dl.begellhouse.com
Rituximab, a chimeric mouse/human monoclonal antibody (mAb) targeting CD20, has
proven to improve treatment outcomes in a number of B-cell malignancies, including chronic …

[PDF][PDF] The Value of C-Reactive Protein, C-Reactive Protein Kinetics and C-reactive Protein to Albumin Ratio on Prognosis in Newly Diagnosed Indolent B-cell Non …

H Zhang, X Zhou, X Sun, Y Han, X Hu, X Yun, Y Zhang… - 2020 - scholar.archive.org
Objective: This study aimed to determine prognostic signi cance of C-reactive protein (CRP),
CRP kinetics and CRP to albumin ratio (CAR) in indolent B-cell non-Hodgkin lymphoma (B …